examine MPXV与免疫原性VACV衍生肽之间的同源性
为评估痘病毒(VACV)衍生肽与猴痘病毒(MPXV)的同源性,本研究通过质谱鉴定152条VACV衍生肽,分析其与MPXV-1和MPXV-2序列的同源性。发现93条(61.2%)序列与两个分支均100%同源,支持痘病毒间因序列同源性导致免疫交叉反应的长期假说,并提示VACV衍生肽可用于猴痘肽基疫苗候选。
要点
- 152条VACV衍生肽中93条(61.2%)与MPXV-1和MPXV-2均100%同源。
- 结果支持痘病毒间免疫交叉反应源于序列同源性的假说。
- VACV衍生肽或可用于猴痘肽基疫苗候选。
核心结论
- 93条(61.2%)VACV衍生肽与MPXV-1和MPXV-2均100%同源,支持痘病毒间免疫交叉反应源于序列同源性的假说。
- 结果提示VACV衍生肽可用于猴痘肽基疫苗候选。
研究设计与样本
- 通过质谱鉴定152条VACV衍生肽,分析其与MPXV-1和MPXV-2序列的同源性。
主要发现
- 152条VACV衍生肽中,93条(61.2%)与MPXV-1和MPXV-2均100%同源。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity. We found that 93 (61.2 %) of these sequences were 100 % homologous to both clades. This supports the long-standing hypothesis that immunologic cross-reactivity is due to sequence homology between poxviruses. Our results also suggest the utility of VACV-derived peptides for an mpox peptide-based vaccine candidate. The development of peptide-based vaccines against MPXV could offer significant advantages over currently available vaccines, such as no cold chain requirement, stability, and reduced manufacturing costs.
引用
- Teodoro LI, Ovsyannikova IG, Poland GA, et al. Examining homology between MPXV and immunogenic VACV-derived peptides. Vaccine. 2025. PMID: 39809088. doi:10.1016/j.vaccine.2025.126708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。